Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etakafusp alfa - Asher Biotherapeutics

Next Previous
Drug Profile

Etakafusp alfa - Asher Biotherapeutics

Alternative Names: AB-248

Latest Information Update: 28 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asher Biotherapeutics
  • Class Anti-infectives; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Feb 2026 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 28 Feb 2026 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (IV, Infusion)
  • 06 Oct 2025 AstraZeneca plans a phase Ib/II ALTAIR trial for Non-small cell lung cancer (Metastatic disease, Late-stage disease, Combination therapy) in USA, Belgium, Brazil, China, France, Georgia, Italy, Japan, Malaysia, Moldova, Netherlands, Peru, Poland, Serbia, South Korea, Spain, Taiwan, Thailand and Turkey (IV), in October 2025 (NCT06996782)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top